仟源医药 reported revenue of ¥0.35B for the period ended 2026-06-30, -5.7% year on year. Net income was ¥0.01B, a 3.3% net margin on a 66.4% gross margin. The largest revenue line is 销售商品 at 98% of the total. Free cash flow for the period was ¥0.05B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.35B | -5.7% |
| Gross profit | ¥0.23B | — |
| Operating income | ¥0.01B | — |
| Net income | ¥0.01B | -28.3% |
| Gross margin | 66.4% | Net margin 3.3% |
| Revenue Q/Q | +2.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| 销售商品 | ¥0.35B | 98.2% |
| 提供劳务 | ¥0.00B | 1.4% |
| 租赁收入 | ¥0.00B | 0.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.12B | 33.6% |
| R&D | ¥0.02B | 7.0% |
| SG&A | ¥0.18B | 51.5% |
| Tax & other | ¥-0.00B | -0.5% |
| Item | Amount |
|---|---|
| Total assets | ¥1.53B |
| Total liabilities | ¥1.00B |
| Shareholders' equity | ¥0.53B |
| Equity / assets | 34.5% |
| Operating cash flow | ¥0.06B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.05B |
| Cash conversion (OCF / net income) | 692% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
常山药业 ・ 星星科技 ・ 开山股份 ・ 精锻科技 ・ 新天科技 ・ 新莱应材 ・ 雅本化学 ・ 隆华科技 ・ 佳创视讯 ・ 通光线缆 ・ 兴源环境 ・ 尔康制药
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies